Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

Author： Sievers Eric L  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.1, Iss.5, 2001-09, pp. : 893-901

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

By Stasi Roberto  

Expert Opinion on Biological Therapy, Vol. 8, Iss. 4, 2008-04 ,pp. : 527-540

Informa Healthcare

Access to resources Recommend Favorite

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

By Breccia Massimo   Lo-Coco Francesco  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 2, 2011-02 ,pp. : 225-234

Informa Healthcare

Access to resources Recommend Favorite

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia

By Hütter Marie-Luise   Schlenk Richard F  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 10, 2011-10 ,pp. : 1369-1380

Informa Healthcare

Access to resources Recommend Favorite

Antibody-based treatment of acute myeloid leukaemia

By Mulford Deborah A   Jurcic Joseph G  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 1, 2004-01 ,pp. : 95-105

Informa Healthcare

Access to resources Recommend Favorite

MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis

By Doxani Chrysoula  

Biomarkers, Vol. 18, Iss. 5, 2013-08 ,pp. : 425-435

Informa Healthcare

Access to resources Recommend Favorite